# Patient-Trial Match Report

*Generated: 2026-01-05 07:00:17*

## Patient Profile

- **Age**: 82
- **Sex**: Male
- **Cancer Type**: chronic lymphocytic leukemia
- **Biomarkers**: TP53 deletion, IGHV unmutated

**Clinical Description**:
> 82-year-old male with relapsed/refractory CLL, high-risk features including del(17p)/TP53 and unmutated IGHV. Previously treated with BR (bendamustine/rituximab) x6 cycles, then ibrutinib x3 years with eventual progression. Venetoclax initiated but discontinued after 4 months due to tumor lysis syndrome requiring hospitalization. Now with progressive lymphadenopathy and cytopenias (ANC 0.8, Hgb 8.9, Plt 67k). Limited by fatigue and reduced mobility - uses walker, needs assistance with ADLs. Multiple comorbidities: CHF (EF 35%), afib on anticoagulation, T2DM, CKD stage 3b.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 12
- **Total trials evaluated**: 65
- **Excluded by fast filter**: 27
- **LLM scored**: 38

## Excluded (65 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT05876923](https://clinicaltrials.gov/study/NCT05876923) | Patient age 82 is above maximum age 80 |
| [NCT03263572](https://clinicaltrials.gov/study/NCT03263572) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04521231](https://clinicaltrials.gov/study/NCT04521231) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04588922](https://clinicaltrials.gov/study/NCT04588922) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04746209](https://clinicaltrials.gov/study/NCT04746209) | Patient age 82 is above maximum age 25 |
| [NCT04792489](https://clinicaltrials.gov/study/NCT04792489) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05082519](https://clinicaltrials.gov/study/NCT05082519) | Patient age 82 is above maximum age 25 |
| [NCT05442515](https://clinicaltrials.gov/study/NCT05442515) | Patient age 82 is above maximum age 39 |
| [NCT05650723](https://clinicaltrials.gov/study/NCT05650723) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05800210](https://clinicaltrials.gov/study/NCT05800210) | Patient age 82 is above maximum age 39 |
| [NCT05959434](https://clinicaltrials.gov/study/NCT05959434) | Patient age 82 is above maximum age 70 |
| [NCT06680661](https://clinicaltrials.gov/study/NCT06680661) | Patient age 82 is above maximum age 65 |
| [NCT06815003](https://clinicaltrials.gov/study/NCT06815003) | Patient age 82 is above maximum age 80 |
| [NCT06839456](https://clinicaltrials.gov/study/NCT06839456) | Patient age 82 is above maximum age 25 |
| [NCT01962636](https://clinicaltrials.gov/study/NCT01962636) | Patient age 82 is above maximum age 55 |
| [NCT02333604](https://clinicaltrials.gov/study/NCT02333604) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03595917](https://clinicaltrials.gov/study/NCT03595917) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04545762](https://clinicaltrials.gov/study/NCT04545762) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05170399](https://clinicaltrials.gov/study/NCT05170399) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05702645](https://clinicaltrials.gov/study/NCT05702645) | Patient age 82 is above maximum age 39 |
| ... | *and 7 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT05702853](https://clinicaltrials.gov/study/NCT05702853) | Medical University o | ECOG status is 3, whereas the trial requires a status of 0-2. |
| [NCT05254743](https://clinicaltrials.gov/study/NCT05254743) | Loxo Oncology, Inc. | ECOG status is 3, which exceeds the maximum acceptable ECOG status of 2. |
| [NCT05947851](https://clinicaltrials.gov/study/NCT05947851) | Merck Sharp & Dohme  | ECOG performance status of 3 does not meet the requirement of 0 to 2 |
| [NCT06839053](https://clinicaltrials.gov/study/NCT06839053) | Fred Hutchinson Canc | ECOG status of 3 does not meet the required ECOG status of 0-2 |
| [NCT06588478](https://clinicaltrials.gov/study/NCT06588478) | Loxo Oncology, Inc. | ECOG status is 3, which exceeds the maximum allowable ECOG score of 2 |
| [NCT06849713](https://clinicaltrials.gov/study/NCT06849713) | Massachusetts Genera | Patient has prior systemic therapies for CLL, while the trial requires no prior systemic therapy. |
| [NCT06973187](https://clinicaltrials.gov/study/NCT06973187) | BeOne Medicines | ECOG status of 3 does not meet typical eligibility criteria for trials which often require ECOG 0-2. |
| [NCT07218510](https://clinicaltrials.gov/study/NCT07218510) | City of Hope Medical | Patient has prior treatments for CLL. The trial is for treatment-naive patients. |
| [NCT03219450](https://clinicaltrials.gov/study/NCT03219450) | Dana-Farber Cancer I | Patient has a prior history of CLL-directed therapy, which is not allowed as per exclusion criteria. |
| [NCT00923507](https://clinicaltrials.gov/study/NCT00923507) | National Heart, Lung | ECOG performance status is 3, but trial requires 0-2 |
| [NCT04028531](https://clinicaltrials.gov/study/NCT04028531) | Dana-Farber Cancer I | Patient has relapsed/refractory CLL, trial does not specify allowance for previously treated patients. |
| [NCT04215809](https://clinicaltrials.gov/study/NCT04215809) | Ascentage Pharma Gro | ECOG status is 3, while the trial requires ECOG ≤ 2. |
| [NCT05899543](https://clinicaltrials.gov/study/NCT05899543) | Power Life Sciences  | ECOG status is 3, which may prevent the patient from participating in the trial |
| [NCT05418088](https://clinicaltrials.gov/study/NCT05418088) | Sumithira Vasu | ECOG status of 3 exceeds the eligibility requirement of ECOG <= 2. |
| [NCT06916767](https://clinicaltrials.gov/study/NCT06916767) | Paolo Caimi, MD | ECOG status (3) exceeds the trial requirement of <= 2 |
| [NCT07166419](https://clinicaltrials.gov/study/NCT07166419) | Ohio State Universit | ECOG status is 3, while the trial requires ECOG status ≤ 2. |
| [NCT05006716](https://clinicaltrials.gov/study/NCT05006716) | BeOne Medicines | ECOG status of 3 does not meet the eligibility requirement of ECOG 0-2 |
| [NCT04771572](https://clinicaltrials.gov/study/NCT04771572) | Newave Pharmaceutica | Patient's ECOG status is 3, but trial requires ECOG score ≤ 2. |
| [NCT05131022](https://clinicaltrials.gov/study/NCT05131022) | Nurix Therapeutics,  | ECOG status 3 does not meet the trial's requirement of 0-1 for eligibility. |
| [NCT05643235](https://clinicaltrials.gov/study/NCT05643235) | Northwell Health | Patient has documented atrial fibrillation (AF) as he is on anticoagulation - conflicting with exclusion criteria. |
| ... | ... | *and 18 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| TP53 deletion | manual | 1.0 |
| TP53deletion | manual | 0.9 |
| TP53-deletion | manual | 0.9 |
| IGHV unmutated | manual | 1.0 |
| IGHVunmutated | manual | 0.9 |
| IGHV-unmutated | manual | 0.9 |
| chronic lymphocytic leukemia | manual | 1.0 |
| TP53 deletion chronic lymphocytic leukemia | manual | 1.0 |
| IGHV unmutated chronic lymphocytic leukemia | manual | 1.0 |
| TP53 deletion CLL | llm | 0.9 |
| CLL | llm | 0.8 |
| del(17p) | llm | 0.9 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
